Semaglutide Slows Breast Cancer Growth by Boosting Anti-Tumor Immune Response in Mice

Semaglutide decelerated tumor appearance and growth in 4T1 breast cancer mice. No direct cytotoxic effect in vitro and no angiogenic effect. NK cell depletion did not affect tumor growth in treated mice. Semaglutide increased CD11c+ dendritic cell accumulation and maturation, decreased FoxP3+ regulatory T cells (in spleen and tumor), increased tumor-infiltrating T cells with anti-tumor phenotype, and enhanced CD8+ T cell cytotoxic capacity.

In vivo mouse study: 4T1 breast cancer cells implanted in BALB/c mice, treated with intraperitoneal semaglutide. In vitro cytotoxicity and angiogenesis assays. NK cell depletion experiments. Flow cytometry analysis of dendritic cells, regulatory T cells, and tumor-infiltrating T cells in spleen and primary tumor. In vitro CD8+ T cell cytotoxicity assays.

The finding that a widely-used GLP-1 drug enhances anti-tumor immunity is remarkable and has immediate clinical implications. With millions of patients taking semaglutide for diabetes and obesity, understanding its effects on cancer risk and progression is critical. This study suggests semaglutide may have cancer-protective effects through immunomodulation.

Epidemiological studies have hinted that GLP-1 RA users may have lower cancer incidence. This study provides a biological mechanism — semaglutide enhances anti-tumor immunity rather than directly attacking cancer cells. If confirmed in humans, this could mean that the millions of people taking semaglutide for metabolic conditions are also receiving cancer-protective immune benefits.

Mouse breast cancer model (4T1) may not fully represent human breast cancer biology or immune responses. Intraperitoneal administration differs from standard subcutaneous dosing. The study didn't assess whether semaglutide's effects depend on weight loss or metabolic changes. Single tumor model — effects may vary across cancer types. No human data on anti-tumor immune effects of semaglutide.